268 related articles for article (PubMed ID: 29195742)
1. Preclinical models to assess the immunogenicity of AAV vectors.
Ertl HCJ
Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742
[TBL] [Abstract][Full Text] [Related]
2. T Cell-Mediated Immune Responses to AAV and AAV Vectors.
Ertl HCJ
Front Immunol; 2021; 12():666666. PubMed ID: 33927727
[TBL] [Abstract][Full Text] [Related]
3. The Effect of CpG Sequences on Capsid-Specific CD8
Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
[TBL] [Abstract][Full Text] [Related]
4. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Li H; Murphy SL; Giles-Davis W; Edmonson S; Xiang Z; Li Y; Lasaro MO; High KA; Ertl HC
Mol Ther; 2007 Apr; 15(4):792-800. PubMed ID: 17245353
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
6. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Vandamme C; Adjali O; Mingozzi F
Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
[TBL] [Abstract][Full Text] [Related]
9. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2007 Oct; 7(5):316-24. PubMed ID: 17979678
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and toxicity of AAV gene therapy.
Ertl HCJ
Front Immunol; 2022; 13():975803. PubMed ID: 36032092
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to adeno-associated virus vectors.
Zaiss AK; Muruve DA
Curr Gene Ther; 2005 Jun; 5(3):323-31. PubMed ID: 15975009
[TBL] [Abstract][Full Text] [Related]
12. CpG-depleted adeno-associated virus vectors evade immune detection.
Faust SM; Bell P; Cutler BJ; Ashley SN; Zhu Y; Rabinowitz JE; Wilson JM
J Clin Invest; 2013 Jul; 123(7):2994-3001. PubMed ID: 23778142
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
14. Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy.
Ertl HCJ; High KA
Hum Gene Ther; 2017 Apr; 28(4):328-337. PubMed ID: 28042943
[TBL] [Abstract][Full Text] [Related]
15. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome.
Wu TL; Li H; Faust SM; Chi E; Zhou S; Wright F; High KA; Ertl HC
Mol Ther; 2014 Jan; 22(1):42-51. PubMed ID: 24077034
[TBL] [Abstract][Full Text] [Related]
16. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
17. Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: possibilities and limitations.
Selot RS; Hareendran S; Jayandharan GR
Curr Pharm Biotechnol; 2014; 14(12):1072-82. PubMed ID: 24678652
[TBL] [Abstract][Full Text] [Related]
18. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.
Verdera HC; Kuranda K; Mingozzi F
Mol Ther; 2020 Mar; 28(3):723-746. PubMed ID: 31972133
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.
Masat E; Pavani G; Mingozzi F
Discov Med; 2013 Jun; 15(85):379-89. PubMed ID: 23819952
[TBL] [Abstract][Full Text] [Related]
20. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice.
Zhu J; Huang X; Yang Y
J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]